Le paludisme est une maladie tropicale causée par un parasite du genre Plasmodium. Chez l’Homme, un niveau élevé de phospholipase A2 sécrétée de groupe IIA humaine (hGIIA) est mesuré dans le plasma des patients impaludés. Cette enzyme est connue pour son rôle antibactérien et pro-inflammatoire. Cependant, son rôle dans le paludisme n’a jamais été exploré. Pour comprendre le rôle in vivo de la hGIIA dans cette pathologie, nous avons entrepris la caractérisation hématologique, histopathologique et immunohistochimique de l’infection de souris C57BL/6, transgéniques (Tg+) pour l’enzyme humaine, par l’espèce murine Plasmodium chabaudi chabaudi 864VD. Ce modèle reproduit un paludisme non létal. Nos résultats ont permis d’établir que les souris Tg+ ont un meilleur contrôle de l’infection au moment du pic de crise parasitaire (J14 post-inoculation), avec une diminution de 27% de la parasitémie, comparé aux souris « littermates » non transgéniques (Tg-). L’injection de hGIIA recombinante aux jours 12, 13 et 14 p.i. (0,125 mg/kg deux fois par jour) à des souris C57BL/6 wild-type (WT) infectées par P. c. chabaudi 864VD provoque une diminution d’environ 19% de la parasitémie à J14 p.i., démontrant un rôle direct de la hGIIA dans la diminution de la population parasitaire. Les données hématologiques montrent que l’infection chez la souris Tg+ provoque une anémie plus durable que chez la souris Tg- et une élévation nettement plus importante du nombre de leucocytes, en particulier des polynucléaires neutrophiles. Chez la souris Tg+ parasitée, on observe aussi l’activation d’un nombre important de lymphocytes et une activation spécifique des monocytes avant le pic de crise. Chez la souris Tg- infectée, les données histologiques mettent en avant une meilleure récupération des lésions histopathologiques du foie et une hyperplasie des lymphocytes B dans la rate, tandis que les souris Tg+ infectées présentent des lésions hépatiques tardives et une hématopoïèse extramédullaire splénique. Les résultats des analyses par RT-qPCR suggèrent que l’ARNm de la hGIIA augmente au pic parasitaire dans le foie des souris Tg+ infectées, mais diminue dans la rate et les cellules sanguines. L’injection de hGIIA recombinante au début de la phase patente est sans effet sur la parasitémie, ce qui laisse supposer que des événements plus tardifs dans l’infection sont nécessaires à l’activité antiparasitaire de l’enzyme. L’étude du rôle des lipoprotéines oxydées comme substrat potentiel de l’activité antiparasitaire de l’enzyme, basée sur des résultats in vitro, est abordée. En conclusion, nos études ont permis de dresser un tableau large de l’infection à Plasmodium chez la souris exprimant la hGIIA, et ouvrent de nouvelles perspectives dans l’analyse du rôle de l’enzyme dans la physiopathologie du paludisme. / Malaria is a tropical disease caused by a parasite of the Plasmodium genus. High levels of circulating human group IIA secreted phospholipase A2 (hGIIA) have been reported in malaria patients. The enzyme is well known for its bactericidal and pro-inflammatory actions. However, so far its role in malaria is unknown. In order to address the in vivo role of hGIIA in malaria, we performed a hematological, histopathological and immunohistochemical characterization of C57BL/6 hGIIA transgenic mice (Tg+ mice) infected with P. chabaudi chabaudi (864VD strain), a murine Plasmodium species and strain which causes non-lethal chronic malaria. Infected Tg+ mice present a 27% reduction of parasitaemia at the peak of infection (D14 post-inoculation, p.i.) compared to infected non-transgenic littermates (Tg- mice). Intraperitoneal injection of recombinant hGIIA at D12, D13 and D14 p.i. (0.125 mg/kg twice a day) into P. chabaudi 864VD-infected WT C57BL/6 mice leads to a 19% reduction of the parasitaemia at D14 p.i., demonstrating the direct and acute role of hGIIA in lowering parasite population and presumably ruling out a potential effect linked to chronic overexpression of hGIIA in Tg+ mice. Hematological data show a durable anemia in Tg+ mice compared to Tg- mice during the infection and an important increase of leucocytes, especially of polynuclear neutrophils. The parasitized Tg+ mouse also presents a higher activation of lymphocytes and a specific activation of monocyte cells at the pic of crisis. In the infected Tg- mouse, histological data show a better histopathological recovery in the liver and B cells hyperplasia in the spleen, whereas the infected Tg+ mouse presents late hepatic injuries and splenic extra-medullar hematopoiesis. RT-qPCR analyses suggest that hGIIA mRNA increases at the pic of infection in the liver of infected Tg+ mice, but decreases in spleen and blood. Intraperitoneal injection of recombinant hGIIA at the patent phase is without effect on parasitaemia, which suggests that later infection events are needed for the enzyme antiparasitic activity. Involvement of oxidized-lipoproteins as potential hGIIA substrates, based on in vitro studies, is discussed. In conclusion, our studies allowed us to elaborate a larger picture of the infection of Plasmodium in the mice expressing hGIIA and open new perspectives in the analysis of the role of the enzyme in malaria pathophysiology.

Os efeitos da MT-I, uma fosfolipase A2 isolada do veneno de Bothrops asper (VBa), foram avaliados em mastócitos (MC) em cultura, quanto à: i) desgranulação e liberação de prostaglandina E2 (PGE2); ii) papel da atividade catalítica na desgranulação; iii) papel da PLD, PLC, cPLA2, iPLA2, PI3K, MAPK, PKC, PTK, ERK1/2, Junk, Gαi, Gαq e do cálcio na desgranulação; iv) expressão gênica de citocinas Th1 e Th2, e v) alterações ultraestruturais em MC. Os resultados mostraram que a MT-I, em concentrações não citotóxicas, causou a desgranulação de MC. Este efeito foi parcialmente dependente da atividade catalítica e dependente da cPLA2, PLC, PLD e PI3K, mas não da iPLA2, ERK1/2, p38MAPK, PKC, MEK, Junk, Gαi e Gαq. O cálcio intra e extracelular (CRAC e LTCC) estão envolvidos neste efeito da MT-I. Ainda, a MT-I induziu a síntese e liberação da PGE2, expressão de genes de citocinas Th1 e Th2, aumento do número de vesículas citoplasmáticas e de endocitose dependente de clatrina. O VBa também causou a desgranulação de MC sugerindo que a MT-I é relevante para este efeito. / The effects of Myotoxin-I (MT-I), a phospholipase A2 (PLA2) from Bothrops asper venom (BaV) in cultured mast cells (MC) were evaluated focusing: i) degranulation and prostaglandin E2 (PGE2) release; ii) role of PLA2 catalytic activity in degranulation; iii) role of PLD and PLC, cPLA2 and iPLA2, PI3K, MAPK, PKC, PTK, ERK1/2, Junk, Gαi and Gαq protein and calcium in degranulation; iv) gene expression of Th1 and Th2 cytokines, and v) MC ultrastructural alterations. Results showed that MT-I, at non-cytotoxic concentrations, caused MC degranulation. This effect was partially dependent on its catalytic activity and dependent on cPLA2, PLC, PLD and PI3K, but not iPLA2, ERK1/2, p38MAPK, PKC, MEK, Junk, Gαi nor Gαq. Both intra and extracellular calcium (CRAC and LTCC) are involved in MT-I-induced degranulation. Furthermore, MT-I induced synthesis and release of PGE2, gene expression of Th1 and Th2 cytokines, increased numbers of cytoplasmic vesicles and clathrin-dependent endocytosis. BaV also caused MC degranulation suggesting that MT-I is relevant for this effect.

Os efeitos da MT-I, uma fosfolipase A2 isolada do veneno de Bothrops asper (VBa), foram avaliados em mastócitos (MC) em cultura, quanto à: i) desgranulação e liberação de prostaglandina E2 (PGE2); ii) papel da atividade catalítica na desgranulação; iii) papel da PLD, PLC, cPLA2, iPLA2, PI3K, MAPK, PKC, PTK, ERK1/2, Junk, Gαi, Gαq e do cálcio na desgranulação; iv) expressão gênica de citocinas Th1 e Th2, e v) alterações ultraestruturais em MC. Os resultados mostraram que a MT-I, em concentrações não citotóxicas, causou a desgranulação de MC. Este efeito foi parcialmente dependente da atividade catalítica e dependente da cPLA2, PLC, PLD e PI3K, mas não da iPLA2, ERK1/2, p38MAPK, PKC, MEK, Junk, Gαi e Gαq. O cálcio intra e extracelular (CRAC e LTCC) estão envolvidos neste efeito da MT-I. Ainda, a MT-I induziu a síntese e liberação da PGE2, expressão de genes de citocinas Th1 e Th2, aumento do número de vesículas citoplasmáticas e de endocitose dependente de clatrina. O VBa também causou a desgranulação de MC sugerindo que a MT-I é relevante para este efeito. / The effects of Myotoxin-I (MT-I), a phospholipase A2 (PLA2) from Bothrops asper venom (BaV) in cultured mast cells (MC) were evaluated focusing: i) degranulation and prostaglandin E2 (PGE2) release; ii) role of PLA2 catalytic activity in degranulation; iii) role of PLD and PLC, cPLA2 and iPLA2, PI3K, MAPK, PKC, PTK, ERK1/2, Junk, Gαi and Gαq protein and calcium in degranulation; iv) gene expression of Th1 and Th2 cytokines, and v) MC ultrastructural alterations. Results showed that MT-I, at non-cytotoxic concentrations, caused MC degranulation. This effect was partially dependent on its catalytic activity and dependent on cPLA2, PLC, PLD and PI3K, but not iPLA2, ERK1/2, p38MAPK, PKC, MEK, Junk, Gαi nor Gαq. Both intra and extracellular calcium (CRAC and LTCC) are involved in MT-I-induced degranulation. Furthermore, MT-I induced synthesis and release of PGE2, gene expression of Th1 and Th2 cytokines, increased numbers of cytoplasmic vesicles and clathrin-dependent endocytosis. BaV also caused MC degranulation suggesting that MT-I is relevant for this effect.

Le squelette 1,3,5-triazépane-2,6-dione est un hétérocycle à sept chainons dérivé de dipeptides et accessible en quatre étapes en solution. Une voie de synthèse en parallèle sur support solide de cet hétérocycle a été élaborée. Cette synthèse, qui repose sur les principes de "catch and release" et de cyclo-clivage, a permis la création d’une chimiothèque de plus d’une centaine de composés. Pour augmenter la diversité du squelette 1,3,5-triazépane-2,6-dione, des modifications post-cyclisation peuvent avoir lieu telles que des réactions de N-mono-alkylation ou de N,N-di-alkylation de l’urée, des réactions d’acylation ou bien des réactions de thionation des fonctions carbonyles. De même, la synthèse des cycles analogues aux 1,3,5-triazépane-2,6-diones des tailles plus importantes a été examinée conduisant à l’obtention de plusieurs macrocycles.Les 1,3,5-triazépane-2,6-diones présentent un fort potentiel pour la recherche de molécules d’intérêt thérapeutique puisque le cycle est rigide, non-planaire et possède une bonne capacité de distribution des pharmacophores dans l’espace. Des molécules de cette famille présentent une activité inhibitrice modérée mais spécifique sur les phospholipases A2 secrétées humaines de type V et X. La recherche de nouveaux inhibiteurs de sPLA2 par une étude de relation structure/activité, par création d’une pince à calcium ou par simulation moléculaire a conduit à l’identification de nouveaux composés actifs. / The 1,3,5-triazepane-2,6-dione scaffold is a seven membered heterocycle derived from dipeptides and accessible in a four steps synthesis in solution. A parallel solid phase synthesis of this heterocycle was developed. This strategy, based on "catch and release" and cyclo-cleavage processes, had created a library containing more than one hundred compounds. To increase the diversity of 1,3,5-triazepane-2,6-dione moieties, some post-cyclisation modifications were performed, e.g. urea N-mono-alkylation or N,N-di-alkylation, acylation, and carbonyl thionation. Synthesis of larger cycles was also investigated and several macrocycles were obtained.The 1,3,5-triazepane-2,6-diones have a strong pharmacological interest, because their cycle is rigid, non-planar and can allow multiple presentation of pharmacophores in space. Some 1,3,5-triazepane-2,6-diones have shown a small but specific activity on the groups V and X of the human secreted phospholipases A2. Structure/activity relationships, clamp synthesis to bind calcium or virtual screening were the strategies used to identify new active compounds.